| Identification | Back Directory | [Name]
Telratolimod | [CAS]
1359993-59-1 | [Synonyms]
Telratolimod
Octadecanamide, N-[4-[(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy]butyl]- | [Molecular Formula]
C36H59N5O2 | [MDL Number]
MFCD31692360 | [MOL File]
1359993-59-1.mol | [Molecular Weight]
593.89 |
| Chemical Properties | Back Directory | [density ]
1.08±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: slightly soluble; Ethanol: slightly soluble | [form ]
A crystalline solid | [pka]
16.28±0.46(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity[1]. | [in vivo]
Telratolimod (50 μg) inhibits the tumor volume, and more potently blocks tumor gowth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 μg) plus 200 μg of CpG ODN slows tumor growth and prolongs survival of mice bearing large tumors[1]. | [IC 50]
TLR7; TLR8 | [References]
[1] Zhao BG, et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12. DOI:10.1186/2051-1426-2-12 |
|
|